Freeline Therapeutics To Start FLT180a Dose Confirmation Study In Hemophilia B By 2021 End

  • Freeline Therapeutics Holdings Plc (NASDAQ: FRLN) has modified its FLT180a clinical development plan for Hemophilia B to address feedback received from the FDA regarding the characterization and comparability of FLT180a used in its Phase 1/2 B-AMAZE trial.
  • Freeline now plans to conduct dose confirmation in a Phase 1/2 trial instead of Phase 2b part of the previously planned Phase 2b/3 trial. The dose confirmation trial could commence by the end of 2021.
  • Data readout for the Phase 1/2 dose confirmation trial is expected by the end of 2022. Phase 3 study is expected to start by the middle of 2023, and filing of a marketing application is anticipated by the end of 2024.
  • The Phase 1/2 dose confirmation trial will be a six-month single-dose safety and efficacy trial designed to confirm the dose and immune management regimen for the planned Phase 3 pivotal trial. Informed by the dose-ranging B-AMAZE trial results, which demonstrated a dose-response across four cohorts, the Company believes that a dose of FLT180a between 7.5e11 and 9.75e11 vg/kg is likely to bring patients into the normal range of Factor IX activity level of 50-150%.
  • Price Action: FRLN stock is trading lower by 6.06% at $16.29 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsSmall CapFDAGeneralhemophilia B
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!